0.87
Scinai Immunotherapeutics Ltd Adr stock is traded at $0.87, with a volume of 31,004.
It is down -4.50% in the last 24 hours and down -42.38% over the past month.
Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units, one focused on in-house development of inflammation and immunology (I&I) biological therapeutic products beginning with a pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO providing services to help biotech companies efficiently bring their products to market by leveraging Scinai's drug development and GMP and non-GMP manufacturing capabilities for pre-clinical and clinical studies. The company generates maximum revenue from the provision of CDMO (Contract Development and Manufacturing Organization) services.
See More
Previous Close:
$0.911
Open:
$0.91
24h Volume:
31,004
Relative Volume:
0.34
Market Cap:
$2.77M
Revenue:
-
Net Income/Loss:
$-9.29M
P/E Ratio:
-0.1673
EPS:
-5.2
Net Cash Flow:
$-9.42M
1W Performance:
-11.09%
1M Performance:
-42.38%
6M Performance:
-69.58%
1Y Performance:
-71.19%
Scinai Immunotherapeutics Ltd Adr Stock (SCNI) Company Profile
Name
Scinai Immunotherapeutics Ltd Adr
Sector
Industry
Phone
972-8-9302529
Address
JERUSALEM BIOPARK, 2ND FLOOR, JERUSALEM
Compare SCNI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
SCNI
Scinai Immunotherapeutics Ltd Adr
|
0.87 | 3.16M | 0 | -9.29M | -9.42M | -5.20 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Scinai Immunotherapeutics Ltd Adr Stock (SCNI) Latest News
SCNI | Scinai Immunotherapeutics Ltd. ADR SEC Filings - MarketWatch
Scinai Immunotherapeutics schedules annual meeting for December 22 - Investing.com
Scinai Immunotherapeutics schedules annual meeting for December 22 By Investing.com - Investing.com South Africa
Cash per share of Scinai Immunotherapeutics Ltd. Sponsored ADR – BER:2F5 - TradingView
Scinai receives $246,000 grant to expand biotech manufacturing By Investing.com - Investing.com South Africa
Scinai receives $246,000 grant to expand biotech manufacturing - Investing.com
Scinai Immunotherapeutics (NASDAQ: SCNI) Reports First-Half 2025 Results, Strengthened Cash Position - Barchart.com
Scinai Reports Six-Month 2025 Financial Results Highlighting Continued CDMO Revenue Growth and Strengthened Balance Sheet - Barchart.com
Scinai Immunotherapeutics (NASDAQ:SCNI) Trading Down 3.8% – Here’s What Happened - Defense World
Scinai Immunotherapeutics Ltd ADR (SCNI) Stock: Uncovering 52-Week Market Trends - investchronicle.com
Scinai Immunotherapeutics (NASDAQ: SCNI) Publishes Peer-Reviewed Data Supporting PC111 as Potential Disease Modifier - Barchart.com
Scinai Immunotherapeutics stock soars on promising skin disease drug data By Investing.com - Investing.com South Africa
Scinai Immunotherapeutics stock soars on promising skin disease drug data - Investing.com Australia
Scinai’s PC111 antibody shows promise for pemphigus treatment By Investing.com - Investing.com Canada
Scinai’s PC111 antibody shows promise for pemphigus treatment - Investing.com India
ICICI Bank Ltd. ADR (IBN) Stock: Navigating a Year of Stock Volatility - investchronicle.com
Scinai Announces New Peer-Reviewed Publication Supporting PC111 as a Disease-Modifying Therapy for Pemphigus and SJS/TEN - Benzinga
Scinai Immunotherapeutics (SCNI) FDA Approvals, PDUFA Dates & Drug Alerts 2025 - MarketBeat
Augusta Gold (TSE:G) Shares Pass Below Two Hundred Day Moving Average – Time to Sell? - Defense World
Scinai Immunotherapeutics Faces Financial Challenges, Seeks Growth - TipRanks
Scinai Immunotherapeutics Reports Strong CDMO Growth - TipRanks
Military Breakthrough: BrainChip and Raytheon Land $1.8M Air Force Deal for Next-Gen Radar - Stock Titan
Scinai Immunotherapeutics (NASDAQ: SCNI) Enters Option Agreement to Acquire Italian Biotech Pincell - The Globe and Mail
Scinai Immunotherapeutics (NASDAQ: SCNI) Expands CDMO Operations with New U.S. Subsidiary - The Globe and Mail
Scinai regains Nasdaq compliance, eyes EIB loan conversion - Investing.com
Scinai Immunotherapeutics enacts reverse split to meet Nasdaq rules - Investing.com
symbol__ Stock Quote Price and Forecast - CNN
Scinai Immunotherapeutics (SCNI) Short Interest & Short Float | Updated Nov 2025 - MarketBeat
Scinai Immunotherapeutics (NASDAQ: SCNI) Announces Participation at BIO-Europe Munich 2023 - Barchart.com
SCNI Stock Price and Chart — NASDAQ:SCNI - TradingView
Scinai Immunotherapeutics (SCNI) Stock Price, News & Analysis - MarketBeat
Scinai Immunotherapeutics Ltd Share Price ADR Each Representing 400 Ord Shares SPON - Hargreaves Lansdown
What is the current Price Target and Forecast for Scinai Immunotherapeutics Ltd. Sponsored ADR (SCNI) - Zacks Investment Research
SCNI Stock Price | Scinai Immunotherapeutics Ltd. ADR Stock Quote (U.S.: Nasdaq) - MarketWatch
Scinai Immunotherapeutics Ltd Adr Stock (SCNI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):